Contribute
España
Italia
대한민국
日本
Français
Benzinga
Research
My Stocks
Tools
Free Benzinga Pro Trial
SPY
764.440.02%
QQQ
715.040.02%
BTC/USD
76809.910.0131%
DIA
525.910.02%
GLD
398.290.12%
TLT
80.930.07%

Sagimet Biosciences Inc

SGMTNASDAQ
Trade with Public
Trade with Public
$10.88
-0.18-1.63%
At close: Sep 11, 5:00 PM EST
$10.82
-0.06-0.55%
After Hours: Sep 11, 4:02 PM EST
OverviewNewsEarnings ForecastEventsPrice TargetsFinancialsSentimentOwnershipCompareOptionsStock Report

Sagimet Biosciences Analyst Price Targets

Wall Street analyst price targets and consensus rating for Sagimet Biosciences (SGMT).

Price Target Range — 12 Quarters

Analyst Consensus — 14 Analysts

2S.Buy
11Buy
1Hold
Consensus RatingBuy# Analysts14Avg. Consensus PT$26Upside to Avg. PT+140.1%

Rating Trend — Last 9 Months

Recent Analyst Actions

See all ratings →
DateFirmAnalystActionRating ChangePrice Target
Sep 9, 2026BarclaysEliana MerleUpgradeEqual-Weight→Overweight$8→$18
Sep 9, 2026Cantor FitzgeraldYanni SouroutzidisInitiateOverweight$11
More with Benzinga EdgeGet Access

Analyst Ratings News

This Illumina Analyst Turns Bullish; Here Are Top 5 Upgrades For Wednesday

Analysts upgraded Sagimet, Figure, Illumina, Martin Marietta and Waters, raising price targets and improving ratings.
Avi Kapoor

PRO
Barclays Upgrades Sagimet Biosciences to Overweight, Raises Price Target to $18

Barclays analyst Eliana Merle upgrades Sagimet Biosciences (NASDAQ:SGMT) from Equal-Weight to Overweight and raises the price target from $8 to $18.
Benzinga Newsdesk

PRO
Cantor Fitzgerald Initiates Coverage On Sagimet Biosciences with Overweight Rating, Announces Price Target of $10.71

Cantor Fitzgerald analyst Yanni Souroutzidis initiates coverage on Sagimet Biosciences (NASDAQ:SGMT) with a Overweight rating and announces Price Target of $10.71.
Benzinga Newsdesk

PRO
HC Wainwright & Co. Reiterates Buy on Sagimet Biosciences, Maintains $29 Price Target

HC Wainwright & Co. analyst Brandon Folkes reiterates Sagimet Biosciences (NASDAQ:SGMT) with a Buy and maintains $29 price target.
Benzinga Newsdesk

PRO
Citizens Maintains Market Outperform on Sagimet Biosciences, Raises Price Target to $29

Citizens analyst Jonathan Wolleben maintains Sagimet Biosciences (NASDAQ:SGMT) with a Market Outperform and raises the price target from $12 to $29.
Benzinga Newsdesk

PRO
Canaccord Genuity Maintains Buy on Sagimet Biosciences, Raises Price Target to $56

Canaccord Genuity analyst Edward Nash maintains Sagimet Biosciences (NASDAQ:SGMT) with a Buy and raises the price target from $49 to $56.
Benzinga Newsdesk

Data & APIs: Benzinga APIs · Stock News API · Analyst Ratings API · Company Logo API

Market data provided by Benzinga APIs

Connect With Us
instagramlinkedinyoutubeblueskymastodon
About Benzinga
Market Resources
Trading Tools & Education
Ring the Bell
© 2026 Benzinga | All Rights Reserved